PTPN11突变在急性髓系白血病中的分子、临床及预后意义
研究纳入1725例新诊断急性髓系白血病(除外急性早幼粒细胞白血病)患者,分析PTPN11突变与细胞遗传学异常及基因突变的共存关系及其对强化化疗结局的影响。140例PTPN11突变样本中,该突变最常见与NPM1、DNMT3A和TET2突变共存;在NPM1野生型患者中PTPN11突变与不良结局相关。
要点
- PTPN11突变最常见与NPM1、DNMT3A和TET2突变共存。
- PTPN11突变在inv(3)(q21q26)/t(3;3)(q21;q26)和正常核型患者中较常见,在典型复杂核型和核心结合因子AML中极罕见。
- NPM1野生型AML患者中PTPN11突变与不良结局相关,NPM1突变患者中则不影响结局。
核心结论
- 在NPM1野生型AML患者中,PTPN11突变与不良结局相关,为研究该分子群体的生物学和治疗策略提供了依据。
- PTPN11突变不影响NPM1突变患者的结局,但这些患者较少共存激酶突变(如FLT3-ITD),提示信号通路重叠激活。
研究设计与样本
- 研究纳入1725例新诊断急性髓系白血病(除外急性早幼粒细胞白血病)患者,均入组Cancer and Leukemia Group B/Alliance for Clinical Trials in Oncology试验。
- 研究分析PTPN11突变与细胞遗传学异常及基因突变的共存关系,以及PTPN11突变对强化化疗结局的影响。
- 试验注册号:NCT00048958(CALGB 8461)、NCT00899223(CALGB 9665)、NCT00900224(CALGB 20202)。
主要发现
- 140例PTPN11突变患者样本中,PTPN11最常见与NPM1、DNMT3A和TET2突变共存。
- PTPN11突变在inv(3)(q21q26)/t(3;3)(q21;q26)和正常核型患者中较常见,在典型复杂核型和核心结合因子AML中极罕见。
- PTPN11 N端SH2结构域突变患者的早期死亡率高于磷酸酶结构域突变患者。
- PTPN11突变不影响NPM1突变患者的结局,但这些患者较少共存激酶突变(如FLT3-ITD)。
- 在NPM1野生型AML患者中,PTPN11突变与不良结局相关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Prognostic factors associated with chemotherapy outcomes in patients with acute myeloid leukemia (AML) are extensively reported, and one gene whose mutation is recognized as conferring resistance to several newer targeted therapies is protein tyrosine phosphatase non-receptor type 11 (PTPN11). The broader clinical implications of PTPN11 mutations in AML are still not well understood. The objective of this study was to determine which cytogenetic abnormalities and gene mutations co-occur with PTPN11 mutations and how PTPN11 mutations affect outcomes of patients treated with intensive chemotherapy. We studied 1725 patients newly diagnosed with AML (excluding acute promyelocytic leukemia) enrolled onto the Cancer and Leukemia Group B/Alliance for Clinical Trials in Oncology trials. In 140 PTPN11-mutated patient samples, PTPN11 most commonly co-occurred with mutations in NPM1, DNMT3A, and TET2. PTPN11 mutations were relatively common in patients with an inv(3)(q21q26)/t(3;3)(q21;q26) and a normal karyotype but were very rare in patients with typical complex karyotype and core-binding factor AML. Mutations in the N-terminal SH2 domain of PTPN11 were associated with a higher early death rate than those in the phosphatase domain. PTPN11 mutations did not affect outcomes of NPM1-mutated patients, but these patients were less likely to have co-occurring kinase mutations (ie, FLT3-ITD), suggesting activation of overlapping signaling pathways. However, in AML patients with wild-type NPM1, PTPN11 mutations were associated with adverse patient outcomes, providing a rationale to study the biology and treatment approaches in this molecular group. This trial was registered at www.clinicaltrials.gov as #NCT00048958 (CALGB 8461), #NCT00899223 (CALGB 9665), and #NCT00900224 (CALGB 20202).
引用
- Fobare S, Kohlschmidt J, Ozer HG, et al. Molecular, clinical, and prognostic implications of PTPN11 mutations in acute myeloid leukemia. Blood Adv. 2022. PMID: 34847232. doi:10.1182/bloodadvances.2021006242
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。